Acquisition by Bailey Gregory of 9019 shares of Serina Therapeutics at 9.5 subject to Rule 16b-3

SER Stock   4.79  0.64  15.42%   
Slightly above 55% of Serina Therapeutics' retail investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Serina Therapeutics suggests that some traders are interested. Serina Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Serina Therapeutics. Many technical investors use Serina Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Serina Therapeutics Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Acquisition of 9019 common stock at 9.5 of Serina Therapeutics by Bailey Gregory on 28th of May 2024. This event was filed by Serina Therapeutics with SEC on 2024-05-28. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Serina Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Serina Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Serina Therapeutics Fundamental Analysis

We analyze Serina Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Serina Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Serina Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

EBITDA

EBITDA Comparative Analysis

Serina Therapeutics is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Serina Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Serina Therapeutics stock to make a market-neutral strategy. Peer analysis of Serina Therapeutics could also be used in its relative valuation, which is a method of valuing Serina Therapeutics by comparing valuation metrics with similar companies.

Additional Tools for Serina Stock Analysis

When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.